These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

531 related items for PubMed ID: 17161994

  • 1. Bone health in men receiving androgen deprivation therapy for prostate cancer.
    Eastham JA.
    J Urol; 2007 Jan; 177(1):17-24. PubMed ID: 17161994
    [Abstract] [Full Text] [Related]

  • 2. Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy.
    Israeli RS, Ryan CW, Jung LL.
    J Urol; 2008 Feb; 179(2):414-23. PubMed ID: 18076933
    [Abstract] [Full Text] [Related]

  • 3. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician.
    Higano CS.
    Urol Clin North Am; 2004 May; 31(2):331-52. PubMed ID: 15123412
    [Abstract] [Full Text] [Related]

  • 4. Bone health in prostate cancer patients receiving androgen-deprivation therapy: the role of bisphosphonates.
    Polascik TJ.
    Prostate Cancer Prostatic Dis; 2008 May; 11(1):13-9. PubMed ID: 17923854
    [Abstract] [Full Text] [Related]

  • 5. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer.
    Ross RW, Small EJ.
    J Urol; 2002 May; 167(5):1952-6. PubMed ID: 11956415
    [Abstract] [Full Text] [Related]

  • 6. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.
    Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N.
    J Urol; 2003 Jun; 169(6):2008-12. PubMed ID: 12771706
    [Abstract] [Full Text] [Related]

  • 7. Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy.
    Bhoopalam N, Campbell SC, Moritz T, Broderick WR, Iyer P, Arcenas AG, Van Veldhuizen PJ, Friedman N, Reda D, Warren S, Garewal H.
    J Urol; 2009 Nov; 182(5):2257-64. PubMed ID: 19758618
    [Abstract] [Full Text] [Related]

  • 8. The role of bisphosphonates in men with prostate cancer receiving androgen deprivation therapy.
    Smith MR.
    Oncology (Williston Park); 2004 May; 18(5 Suppl 3):21-5. PubMed ID: 15202584
    [Abstract] [Full Text] [Related]

  • 9. Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma.
    Smith MR.
    Cancer; 2003 Feb 01; 97(3 Suppl):789-95. PubMed ID: 12548577
    [Abstract] [Full Text] [Related]

  • 10. Preservation of bone health in prostate cancer.
    Lattouf JB, Saad F.
    Curr Opin Support Palliat Care; 2007 Oct 01; 1(3):192-7. PubMed ID: 18685362
    [Abstract] [Full Text] [Related]

  • 11. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer.
    Ryan CW, Huo D, Demers LM, Beer TM, Lacerna LV.
    J Urol; 2006 Sep 01; 176(3):972-8; discussion 978. PubMed ID: 16890673
    [Abstract] [Full Text] [Related]

  • 12. Progressive osteoporosis during androgen deprivation therapy for prostate cancer.
    Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT.
    J Urol; 2000 Jan 01; 163(1):181-6. PubMed ID: 10604342
    [Abstract] [Full Text] [Related]

  • 13. Preserving bone health in patients with hormone-sensitive prostate cancer: the role of bisphosphonates.
    Saad F, Abrahamsson PA, Miller K.
    BJU Int; 2009 Dec 01; 104(11):1573-9. PubMed ID: 20053188
    [Abstract] [Full Text] [Related]

  • 14. Bone loss and fracture risk associated with cancer therapy.
    Guise TA.
    Oncologist; 2006 Dec 01; 11(10):1121-31. PubMed ID: 17110632
    [Abstract] [Full Text] [Related]

  • 15. Cancer treatment-induced bone loss in breast and prostate cancer.
    Saad F, Adachi JD, Brown JP, Canning LA, Gelmon KA, Josse RG, Pritchard KI.
    J Clin Oncol; 2008 Nov 20; 26(33):5465-76. PubMed ID: 18955443
    [Abstract] [Full Text] [Related]

  • 16. The role of bisphosphonates in preventing skeletal complications of hormonal therapy.
    Gilbert SM, McKiernan JM.
    Urol Clin North Am; 2006 May 20; 33(2):191-9, vi. PubMed ID: 16631457
    [Abstract] [Full Text] [Related]

  • 17. Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis.
    Saad F, McKiernan J, Eastham J.
    Urol Oncol; 2006 May 20; 24(1):4-12. PubMed ID: 16414486
    [Abstract] [Full Text] [Related]

  • 18. Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know?
    Higano CS.
    Nat Clin Pract Urol; 2008 Jan 20; 5(1):24-34. PubMed ID: 18185511
    [Abstract] [Full Text] [Related]

  • 19. Nursing implications of androgen deprivation therapy-associated bone loss.
    Weingard KK.
    Urol Nurs; 2006 Aug 20; 26(4):261-9; quiz 270. PubMed ID: 16939043
    [Abstract] [Full Text] [Related]

  • 20. Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications.
    Krupski TL, Foley KA, Baser O, Long S, Macarios D, Litwin MS.
    J Urol; 2007 Oct 20; 178(4 Pt 1):1423-8. PubMed ID: 17706711
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.